SVN53-67/M57-KLH peptide vaccine

Drug Profile

SVN53-67/M57-KLH peptide vaccine

Alternative Names: SurVaxM; Survivin peptide mimic vaccine - MimiVax; Survivin-targeted peptide vaccine - MimiVax

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action BIRC5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Multiple myeloma
  • No development reported Glioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Combination therapy) in USA (SC, Injection)
  • 01 Jun 2016 Roswell Park Cancer Institute plans a clinical trial for Multiple myeloma (Combination therapy)
  • 15 Mar 2016 Phase-I clinical trials in Multiple myeloma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top